单剂黏膜免疫治疗用黑猩猩腺病毒载体疫苗加速结核病控制并限制停药后反弹
该研究在小鼠肺结核模型中探讨单次呼吸道黏膜治疗性递送表达Ag85A的黑猩猩腺病毒载体疫苗(AdCh68Ag85A)联合抗生素的效果。结果显示黏膜途径而非胃肠外途径显著加速肺部分枝杆菌清除、限制肺病理并遏制提前停抗生素后的疾病反弹;疫苗激活的抗原特异性T细胞(尤其CD8 T细胞)发挥重要作用。结论提示单剂呼吸道黏膜免疫治疗联合抗生素有望加速疾病控制并缩短常规疗程。
要点
- 单剂呼吸道黏膜AdCh68Ag85A联合抗生素加速肺部分枝杆菌清除并限制肺病理。
- 黏膜途径而非胃肠外途径可限制提前停抗生素后的疾病反弹。
- 疫苗激活的肺内抗原特异性T细胞尤其CD8 T细胞参与免疫治疗效果。
核心结论
- 单剂呼吸道黏膜AdCh68Ag85A联合抗生素治疗有潜力显著加速结核病控制并缩短常规治疗时长。
- 研究为呼吸道途径病毒载体疫苗的治疗性应用提供原理验证。
研究设计与样本
- 采用小鼠肺结核模型开展研究。
- 研究单次呼吸道黏膜治疗性递送表达Ag85A的黑猩猩腺病毒载体疫苗(AdCh68Ag85A)联合抗生素的效果。
主要发现
- 呼吸道黏膜途径而非胃肠外途径的免疫治疗显著加速肺部分枝杆菌清除。
- 黏膜途径免疫治疗限制肺病理并遏制提前(非灭菌性)停抗生素后的疾病反弹。
- 疫苗激活的抗原特异性T细胞尤其CD8 T细胞在肺内发挥重要免疫治疗作用。
临床怎么用
- 提示可在抗生素治疗基础上联合单剂呼吸道黏膜病毒载体疫苗以加速结核病控制。
- 支持进一步探索呼吸道途径治疗性疫苗以缩短常规抗结核疗程。
局限性
- 证据来自小鼠肺结核模型,尚需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The development of strategies to accelerate disease resolution and shorten antibiotic therapy is imperative in curbing the global tuberculosis epidemic. Therapeutic application of novel vaccines adjunct to antibiotics represents such a strategy. METHODS: By using a murine model of pulmonary tuberculosis (TB), we have investigated whether a single respiratory mucosal therapeutic delivery of a novel chimpanzee adenovirus-vectored vaccine expressing Ag85A (AdCh68Ag85A) accelerates TB disease control in conjunction with antibiotics and restricts pulmonary disease rebound after premature (nonsterilizing) antibiotic cessation. RESULTS: We find that immunotherapy via the respiratory mucosal, but not parenteral, route significantly accelerates pulmonary mycobacterial clearance, limits lung pathology, and restricts disease rebound after premature antibiotic cessation. We further show that vaccine-activated antigen-specific T cells, particularly CD8 T cells, in the lung play an important role in immunotherapeutic effects. CONCLUSIONS: Our results indicate that a single-dose respiratory mucosal immunotherapy with AdCh68Ag85A adjunct to antibiotic therapy has the potential to significantly accelerate disease control and shorten the duration of conventional treatment. Our study provides the proof of principle to support therapeutic applications of viral-vectored vaccines via the respiratory route.
引用
- Afkhami S, Lai R, D'agostino MR, et al. Single-Dose Mucosal Immunotherapy With Chimpanzee Adenovirus-Based Vaccine Accelerates Tuberculosis Disease Control and Limits Its Rebound After Antibiotic Cessation. J Infect Dis. 2019. PMID: 31198944. doi:10.1093/infdis/jiz306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。